Press release - 24 May 2022

New transaction carried out by Largillière Finance: Largillière Finance advises BELILAB Laboratories in their merger with BIOPATH Laboratoires

Largillière Finance is assisting BELILAB, a group of private medical laboratories located in the Pas-de-Calais region, in its merger with the BIOPATH Laboratoires group, which thus strengthens its position as an independent leader in the Hauts-de-France region.

BELILAB, which dates back to 1945, operates four laboratories and a technical platform in Béthune, in the Pas-de-Calais region - an arrangement that enables it to perform analyses locally within a short timeframe and that will be maintained in the new group.

BIOPATH Laboratories is the leading independent medical biology group in the Hauts-de-France region with 46 sites organized around 10 technical and emergency platforms, 2 AMP* centers, 46 medical biologists who receive 8,000 patients/day excluding COVID.

By joining BIOPATH Laboratoires, BELILAB will keep its structures and teams, and will become part of a group recognized for its innovative equipment, its ability to organize and adapt, particularly during the COVID crisis, and its proximity to patients and healthcare partners.

The combination of BELILAB's sites with those of BIOPATH Laboratoires will enable the new entity to strengthen its geographical coverage and reinforce its position as the leading independent medical biology company in the Hauts-de-France region, where the healthcare sector is strongly consolidating.

The sale process was led by the teams of Largillière Finance, under an exclusive mandate from BELILAB's shareholders. At the end of a very competitive process, which attracted strong interest from several national and regional players, it was finally BIOPATH Laboratoires that convinced BELILAB's partners.


Shamir Razavhoussen, Associate Director at Largillière Finance 

"The health crisis has underlined, if it were necessary, the essential role of laboratories which must combine quality of analysis and service with geographical proximity, leading to significant needs in terms of equipment, investment in new technologies and support. Largillière Finance has developed a solid expertise in the health sector with several operations to its credit and masters the stakes, which allowed us to fully meet the specifications set by our clients: to select and meet a shortlist of candidates able to ensure BELILAB the sustainability of the teams, the human and technical resources to support its growth and development strategy, as well as the preservation of the company culture".


Nicolas Jacob, biologist, BELILAB

"We were impressed by Largillière Finance's involvement and its perfect command of the healthcare market.
We chose BIOPATH Laboratoires for the convergence of our ideas, our human vision of medical biology and for its ambitions in the Hauts-de-France region. We are delighted with this new step for BELILAB".


Antoine Crinquette, Biologist, CEO of BIOPATH Laboratoires

"We are delighted to be joining forces with BELILAB, with whom we share the same values at the service of patients and healthcare partners, based on independence, responsibility, innovation and excellence. We would also like to thank the BELILAB teams for providing us with their expertise to support our common objective: to guarantee a quality and local healthcare offer by consolidating the independence of medical biology".

With offices in Paris, Lyon, Nantes, Brussels and Geneva, Largillière Finance is an independent investment bank dedicated to assisting managers and shareholders of small and medium-sized companies with their capital transactions: company sales and acquisitions, financing (capital and/or debt), financial engineering (valuation, etc.) and financial strategy.

To read

Communiqués de presse

Press release

Press release


Largillière Finance utilise les informations que vous nous fournissez pour vous contacter au sujet de notre contenu, produits et services pertinents. Vous pouvez vous désinscrire de ces communications à tout moment. Pour plus d’informations, consultez notre politique de confidentialité.